Deciphering the role of the tumor suppressor p53 in regulating treatment-induced ovarian cancer cell fate decisions in vivo
As the most lethal gynaecological cancer, ovarian cancers not only threaten lives of many women worldwide, but health side effects also burdens the life of millions patients following treatments. Novel therapeutic methods aiming at increasing the long-term survival of patients and decreasing health side effects associated with treatment is critical. We have already found that current chemotherapy protocols induce a very interesting phenomenon cellular senescence - in treated cells. Senescence is thought to be beneficial in cancer therapy under certain conditions. We would like to explore the mechanisms of this senescent response to treatment in ovarian cancer and to manipulate it to benefit patients.